Last updated: August 7, 2025
Introduction
Patent IL202835 represents a key element in Israel’s pharmaceutical patent landscape. As part of the intellectual property portfolio, understanding its scope, claims, and positioning within the broader patent environment is crucial for stakeholders, including innovators, generic manufacturers, and legal professionals. This article offers a detailed examination of IL202835, dissecting its claims, assessing its coverage, and contextualizing it within the Israeli and global patent landscapes related to pharmaceuticals.
Patent Overview and Technical Field
Patent IL202835 was granted by the Israel Patent Office (ILPO) and pertains to a specific drug formulation or medical use, according to filings and official patent documents. While precise technical details require review of the patent document itself, patent titles and abstracts suggest that IL202835 is associated with a novel pharmaceutical compound, a drug delivery system, or a therapeutic method.
In general, Israel’s pharmaceutical patent landscape is characterized by proactive patent protections aligned with international standards, including compliance with the Patent Cooperation Treaty (PCT). The patent likely belongs to the category of compound, formulation, or use claims, common in biologics or small-molecule drugs.
Scope of the Patent: Key Aspects
Patent Claims and Their Nature
The scope of IL202835 is primarily dictated by its independent and dependent claims. Although exact claim language is necessary for a detailed analysis, typical patent claims in such a context fall into the following categories:
- Compound Claims: Covering a specific chemical entity or a class of compounds with defined structural features.
- Use Claims: Covering therapeutic methods involving the compound, often claiming a novel medical use.
- Formulation Claims: Covering specific pharmaceutical compositions or delivery systems incorporating the active ingredient.
- Process Claims: Covering synthesis or manufacturing methods for creating the compound or formulation.
Note: Claim language typically defines boundaries, such as chemical structures using Markush groups, functional descriptors, or parameters like molecular weight, substituents, or stereochemistry.
Claim Construction and Limitations
The precise language of IL202835’s claims determines whether they extend to broader classes or are narrowly focused. Broad claims, if allowed, provide extensive protection; narrow claims, while easier to defend, limit scope. The patent likely contains a mixture of broad independent claims and narrower dependent claims, refining scope and reducing invalidity risks.
Patent Term and Patentability
Given its filing status and publication date, IL202835 enjoys up to 20 years of protection from the earliest filing date, subject to maintenance fees. Patentability hinges upon novelty, inventive step, and industrial applicability, all of which the patent office examined prior to granting.
Patent Landscape and Strategic Positioning
Comparison with International Patent Portfolios
Israel’s pharmaceutical patent landscape has rigorous standards, often aligning with European and U.S. patent frameworks. IL202835’s claims probably align with international patent classifications, such as:
- C07D: Heterocyclic compounds
- A61K: Preparations for medical, dental, or veterinary-purpose
- C12N: Microorganisms or enzymes, if biologics are involved
In the global context, patent filings by originators in major markets like the U.S., Europe, and Asia often mirror Israeli claims, especially for blockbuster drugs.
Second-Generation and Follow-On Patents
Patent families in pharmaceuticals often include secondary filings to extend exclusivity, such as formulation improvements or new therapeutic indications. IL202835 could be part of such a family, with subsequent patents refining or broadening scope.
Challenges and Opportunities
The robustness of IL202835’s claims depends on prior art clauses and potential for claim overlap with generics. If claims are broad and well-supported, they can serve as strong barriers; however, narrow claims could face challenges (e.g., validity or infringement issues).
Opportunities exist in licensing, partnerships, or defending against generic entry once patent exclusivity expires.
Legal Status and Enforcement
The legal enforceability of IL202835 depends on its prosecution history, opposition proceedings, and maintenance status. Evidence of challenge or infringement actions would illuminate its strength.
Given Israel’s active patent environment, patent holders might seek to enforce IL202835 via litigation or settlement in case of infringement by competitors or generic manufacturers.
Analysis Summary
| Aspect |
Insights |
| Scope |
Focused on specific chemical compounds, methods, or formulations. Likely includes both product and use claims. |
| Claims |
Likely includes a mix of broad independent claims and narrower dependent claims, centered on chemical structure and therapeutic methods. |
| Patent Landscape |
Positioned within Israel as part of a broader international patent ecosystem, aligned with global pharmaceutical patent standards. |
| Strengths and Risks |
Strong if claims are broad and well-supported; vulnerable if narrow or overlapping prior art. |
| Legal and Commercial Relevance |
Significant potential for market exclusivity; dependent on enforcement and market dynamics. |
Key Takeaways
- Scope Specificity: The commercial value of IL202835 hinges on the breadth and clarity of its claims. Broad claims offer maximum protection but must withstand prior art scrutiny.
- Strategic Positioning: IL202835 should be viewed within comprehensive patent families, with secondary patents extending protection.
- Global Alignment: Its claims and patent strategy likely mirror international filings, reflecting an integrated approach to patent protection.
- Enforcement Potential: Its enforceability depends on its prosecution history and the strength of its claims against potential infringers.
- Market Impact: The patent’s status influences pricing, licensing, and generic entry strategies in Israel and potentially abroad.
FAQs
1. What types of claims are most likely included in IL202835?
IL202835 likely features a combination of compound claims, method-of-use claims, and formulation claims, typical in pharmaceutical patents aiming to cover the active ingredient, its therapeutic application, and its delivery system.
2. How does IL202835 compare to similar patents internationally?
While specific claim scope depends on patent language, Israeli patents in pharmaceuticals tend to align with European and U.S. standards, potentially forming part of broader international patent families.
3. Can IL202835’s claims be challenged or invalidated?
Yes, through prior art-based invalidity proceedings, patent examinations, or opposition actions, especially if prior art demonstrates lack of novelty or inventive step.
4. What strategies can patent holders utilize to strengthen IL202835’s market position?
Filing secondary and continuation patents, maintaining robust enforcement, and leveraging international patent filings can reinforce exclusivity and commercial leverage.
5. When does IL202835’s patent protection expire?
Assuming standard filing timelines and no extensions, protection typically lasts 20 years from the earliest filing date, subject to patent maintenance and national adjustments.
References
[1] Israel Patent Office, Patent database entries.
[2] World Intellectual Property Organization (WIPO), Patent Cooperation Treaty (PCT) publications.
[3] European Patent Office (EPO), Patent landscapes.
[4] General principles of pharmaceutical patent law (e.g., TRIPS Agreement).
